Formulation and Evaluation of Buccoadhesive Drug Delivery System for Lovastatin by THENGE, RAJU RAMESH et al.
Thenge et al                                                                                                                    Journal of Drug Delivery & Therapeutics. 2019; 9(2-s):6-12 
ISSN: 2250-1177                                                                                  [6]                                                                                 CODEN (USA): JDDTAO 
Available online on 15.04.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                     Research Article 
Formulation and Evaluation of Buccoadhesive Drug Delivery System for 
Lovastatin 
R. R. Thenge1*, S. S. Mahajan1, N. M. Mahajan2, V.S. Adhao1, P. V. Ajmire3 
1. Dr. Rajendra Gode College of Pharmcy, Malkapur, Maharashtra, India 
2. Dadasaheb Balpande College of Pharmacy, Besa, Nagpur, Maharashtra,  India 
3. Dr. Rajendra Gode Institute of Pharmcy, Amravati, Maharashtra, India 
 
ABSTRACT 
Lovastatin, a hyperlipedemic agent used in the treatment of hypercholesterolemia, has poor bioavailability ( less than 5%) due to the first pass 
metabolism and thus the dosing frequency is more, as a result of which several side effects occurred with the current dosage form. The present 
study aimed to formulate and evaluate buccoadhesive tablets of Lovastatin using mucoadhesive polymer such as Carbopol 934P, 
Hydroxypropylmethyl cellulose (K4M, K100M) and sodium CMC. The different formulations of buccoadhesive tablet of Lovastatin were prepared 
by direct compression method and characterized for physicochemical parameters such as thickness, content uniformity, weight variation, 
hardness, and friability test. The swelling index, % matrix erosion, surface pH, bioadhesive strength, bioadhesive time and in-vitro drug release 
are also carried out which has been important aspect for success of buccoadhesive tablets. The FTIR study was carried out for drug and polymer 
compatibility.  All the formulation showed satisfactory tablet properties. Formulation (F5) containing Carbopol 934P and HPMC K4M in the ratio 
of (1:1) showed good bioadhesive strength and maximum drug release of 95.80% in 8 hours. The surface pH of all tablets was found to be 
satisfactory, close to buccal pH, hence no irritation would observe with these tablets. FTIR studies showed no evidence of interaction between 
drug and polymers. 
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INTRODUCTION 
Buccal delivery of drugs provides an attractive alternative to 
the oral route of drug administration, particularly in 
overcoming the disadvantages associated with the later 
mode of dosing. Problems such as first pass metabolism and 
drug degradation in the harsh gastrointestinal environment 
can be circumvented by administering drug via buccal route. 
Generally the dosage forms are administered by the oral 
routes, but mostly the various categories of the drug 
undergone hepatic first pass metabolism therefore less 
amount drug reached in to the systemic circulation. 
Moreover, the oral cavity is easily accessible for self 
medication and can be promptly terminated in case of 
toxicity just by removing the dosage form from buccal cavity. 
It is also possible to administer drug to patients who cannot 
be dosed orally via this route.1- 4 
Lovastatin is a class of ‘HMG-CO-A’ reductase inhibitor. It is 
first line of choice for the treatment of hypercholesterolemia, 
when it is given orally it is incompletely absorbed, it has low 
bioavailability (less than 5%) due to extensive hepatic 
metabolism5-8, so the clinically efficacy of drug is less. 
Therefore, drug should be administered frequently. Also it 
has also short half life (1.1-1.7 hrs). Hence an attempt has 
been made to developed sustained drug delivery of 
Lovastatin. So the buccoadhesive drug delivery system is one 
of the best alternatives to avoid first pass metabolism and 
also to prolong the action of drug. Thus, to improve all the 
characteristics of drug candidate by preparing 
buccoadhesive sustained drug delivery system.    
MATERIALS AND METHODS 
Lovastatin was obtained as a gift sample from Watson 
Pharmaceuticals, Goa, India. Carbopol 934P, HPMC K4M, 
HPMC K100M, sodium CMC, EC and MCC was procured from 
Molychem, Mumbai. All other reagent and materials were of 
analytical grade. 
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FTIR study:  
The Lovastatin, physical mixture of Lovastatin and each 
polymer was triturate with dried potassium bromide using 
mortar and pestles; the mixture after grinding in to fine 
powder was kept uniformly in suitable die and compress by 
using hydraulic press at high pressure. The Lovastatin, 
physical mixture of Lovastatin and each polymer were 
scanned and recorded in the range of 4000-400 cm-1 by using 
Infrared spectrophotometer (Brooker, Alfa-T, Germany). 
Preparation of buccoadhesive tablets of Lovastatin: 
Composition of buccoadhesive tablet was shown in Table-1. 
Lovastatin buccoadhesive bi-layer tablet were prepared by 
direct compression method. The drug can be incorporated in 
to the core tablet containing different ratio of mucoadhesive 
polymer and is covered with backing ethyl cellulose layer. All 
the ingredient of the formulation was passed through sieve 
no. 60 and mixing in mortar with a pestle to get uniform 
mixing. The blended powder (150 mg) of core was 
compressed on single stroke multi-station rotary tablet 
punching machine having 8 mm round shaped punch. After 
punching the core layer, upper punch was removed and ethyl 
cellulose (50 mg) was added over it and again compressed to 
obtain backing layer. 
 
Table 1: Composition for Buccoadhesive tablet of Lovastatin 
Ingredients   (mg) 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Lovastatin 20 20 20 20 20 20 20 20 20 
Carbopol 934 P 30 45 60 30 45 60 30 45 60 
Sodium CMC 60 45  30 ----- ----- ----- ----- ----- ----- 
HPMC  K4 M ----- ----- ----- 60 45  30 ----- ----- ----- 
HPMC  K100 M ----- ---- ---- ----- ---- ---- 60 45  30 
Microcrystalline Cellulose 37 37 37 37 37 37 37 37 37 
Magnesium Stearate 2 2 2 2 2 2 2 2 2 
Talc 1 1 1 1 1 1 1 1 1 
Backing layer (EC) 50 50 50 50 50 50 50 50 50 
 
Weight variation: 
Twenty tablets were weighed individually and the average 
weight was calculated. The individual weights were then 
compared with the average weight. The tablet pass the test if 
not more than two tablets fall outside the percentage limit 
and none of the tablets differ by more than double the 
percentage limit9. 
Content uniformity: 
Ten tablets were randomly taken and triturated using glass 
mortar and pestle and accurately   weighed. Exact quantity of 
triturated powder equivalent to 20 mg of drug was taken 
into 50 ml of   volumetric flask and dissolved in minimum 
amount of methanol and made up to the mark with 
phosphate buffer pH 6.8 up to 50 ml. then sample were 
analyzed by using UV spectrophotometer at 238 nm.  
Hardness and Friability: 
The Monsanto hardness tester was used to determine the 
tablet hardness. The hardness of five tablets in each batch 
was measured and the average hardness was calculated. 
Friability was evaluated by Roache friabilator. Twenty 
weighed tablet were placed in the friabilator and then 
operated at 25 rpm for 4 minutes. The tablets were then 
removed and weighed again. The difference in the two 
weights was used to calculate friability9. 
Thickness:  
Take five tablets from each batch of formulation and the 
thickness of the tablets were measured with the help of 
vernier caliper. The average thickness is calculated9. 
Surface pH Study:   
The surface pH of the buccal tablet was determined in order 
to investigate the possibility of any side effects in an oral 
cavity. As acidic or alkaline pH may irritate the buccal 
mucosa, attempt was made to keep the surface pH close to 
the buccal pH. The tablets were allowed to swell for 2 h in 1 
ml of distilled water. The surface pH was measured by 
bringing the electrode in contact with the surface of the 
formulations and allowing it to equilibrate for 1 min10. 
Swelling index: 
From each formulation, single tablet was taken and weighed, 
individually (W1) and placed separately in petridish 
containing 5 ml of phosphate buffer PH 6.8. The petridish 
were kept at room temperature for 30 minutes, then buccal 
tablets were removed from petridish and excess of water 
was removed carefully by using filter paper. The swollen 
buccal tablets were reweighed (W2) and % swelling index 
was calculated using formula11. 
         %Swelling index=     W2-W1/W1×100  
Where,                 W1    -      Initial weight 
                              W2    -      Final weight  
 
Bioadhesion strength:  
Bioadhesive strength of the buccal tablets was measured on 
the “Modified Physical Balance method”. The method used 
goat buccal mucosa as the model mucosal membrane. The 
fresh goat buccal mucosa was cut into pieces and washed 
with phosphate buffer pH 6.8. A piece of mucosa was tied to 
the glass slide which was moistened with phosphate buffer 
pH 6.8. The tablet was stuck to the lower side of another 
glass slide with glue. The both pans were balanced by adding 
an appropriate weight on the left- hand pan. The glass slide 
with mucosa was placed with appropriate support, so that 
the tablet touches the mucosa. On the side of balance powder 
(equivalent to weight) was added slowly to it until the tablet 
detach from the mucosal surface. The weight required to 
detach the tablet from the mucosal surface gave the 
bioadhesive strength. Bioadhesive strength was assessed in 
terms of weight [gm.] required to detach from membrane. 
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Bioadhesion strength which was measured as force of 
adhesion in Newton by using formula12.    
Force of adhesion (N) = Mucoadhesive strength / 100 X 9.81 
Bioadhesion time:  
The in-vitro mucoadhesion time was examined after 
application of the buccal tablet on freshly cut goat buccal 
mucosa. The fresh goat buccal mucosa was tied on the glass 
slide, and a mucoadhesive core side of each tablet was 
wetted with 1 drop of phosphate buffer pH 6.8 and pasted to 
the goat buccal mucosa by applying a light force with a 
fingertip for 30 seconds. The glass slide was then put in the 
beaker, which was filled with 200 ml of the phosphate buffer 
pH 6.8 and kept at 37 ± 1°C. After 2 minutes, stirring was 
applied slowly to simulate the buccal cavity environment, 
and tablet adhesion was monitored for 8 h. The time for the 
tablet to detach from the goat buccal mucosa was recorded 
as the mucoadhesion time13. 
In-vitro drug release: 
The USP dissolution test type II paddle apparatus was used 
to study the drug release from the tablets. The dissolution 
medium was 900ml of phosphate buffer pH 6.8. The release 
was performed at 37 ± 0.5°C, with a rotation speed of 50 
rpm. The backing layer of buccal tablet was attached to the 
glass slide with instant adhesive. The slide was allocated to 
the bottom of the dissolution vessel. 5 ml samples were 
withdrawn at predetermined time intervals and replaced 
with fresh medium. The samples were filtered through 
whatmann filter paper and analyzed after appropriate 
dilution by UV spectrophotometer at 238 nm14. 
Kinetics of in-vitro drug release: 
To study the in-vitro drug release kinetics, data was applied 
to kinetic models such as zero order, first order, Higuchi, 
Hixson Crowell and Korsmeyer- Pappas. 
RESULT AND DISCUSSION 
             The Buccoadhesive drug delivery of lovastatin was prepared 
by direct compression method using different concentration 
of mucoadhesive polymer such as carbopol 934P, sodium 
CMC, HPMC K4M, HPMC K100M. The drug and polymer 
compatibility was studied by FTIR spectroscopy. The FTIR 
spectra of drug and physical mixture of each polymer was 
studied and showed no changes in the peaks of physical 
mixture when compare to standard shown in Fig.1 (a-e). This 
indicates no chemical interaction between the dug and 
polymer. 
 
Table 2: Physical properties for Buccoadhesive tablet of Lovastatin. 
Formulation 
Code 
Drug content 
(%) 
Friability 
(%) 
Thickness 
(mm) 
Average                    
weight   (mg) 
Surface pH 
F1 99.48 ±0.40 0.53 ±0.06 3.21±0.020 209.82 ±0.5 6.88±0.02 
F2 99.98±0.31 0.54 ±0.03 3.21± 0.057 209.66 ±0.5 6.93±0.02 
F3 98.45 ±0.51 0.54 ±0.08 2.88± 0.072 199.00 ±2.0 6.97±0.03 
F4 99.56 ±0.00 0.56 ±0.02 3.21± 0.011 211.66 ±0.5 7.0±0.03 
F5 98.91 ±0.23 0.56 ±0.05 3.22± 0.041 207.74 ±1.5 6.82±0.01 
F6 95.51 ±0.31 0.53 ±0.06 3.24  ± .032 201.33 ±0.5 6.89±0.02 
F7 99.46 ±0.35 0.59 ±0.05 3.22± 0.026 204.56 ±0.5 6.33±0.02 
F8 97.42 ±0.32 0.58 ±0.02 3.24± 0.025 208.69 ±0.5 7.22±0.03 
F9 97.13±0.29 0.55 ±0.06 3.27± 0.026 204.83 ±0.5 6.91±0.03 
 
 
 
Figure 1(a): FTIR Spectrum of Lovastatin 
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Figure 1(b): FTIR Spectrum of physical mixture of Lovastatin and Carbopol 934P 
    
 
Figure 1(c): FTIR Spectrum of physical mixture of Lovastatin and HPMC K4M 
 
 
Figure 1:(d): FTIR Spectrum of physical mixture of  Lovastatin and HPMC K100M 
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Figure 1(e): FTIR Spectrum of formulation blend 
 
The physical properties of the buccoadhesive tablet were 
shown in Table No. 2. The average weight of the tablet was 
found to be in the range of 199.00 mg to 211.66 mg for all 
the formulation. The tablets showed thickness in the range of 
2.88 to 3.24 mm. The percentage drug content of all the 
formulation was found to be 95.51 to 99.98 %. Also the 
tablets have satisfactory hardness and friability values thus 
it has good mechanical strength. Therefore all the 
formulation complies with that of the standard. Surface pH of 
all the formulation was found in the range of 6.33 to 7.0. 
These results reveal that all the formulation have acceptable 
pH in the range of salivary pH (5.5 to 7.0). Thus the 
formulations do not cause any local irritation to the mucosal 
surface. Swelling index of formulations was shown in Fig.2. 
Swelling index was determined with respect to time. The 
swelling index of the tablets was increased with increasing 
concentration of hydrophilic polymer. The polymer absorbed 
large volumes of water rapidly and swells to its maximum 
hydrated size without dissolving in aqueous media. HPMC is 
a hydrophilic polymer which swells slowly to form a gel 
which then dissolves in the presence of water. The gelling 
property of this polymer will provide the binding strength. 
Hence the integrity of tablet was maintained for further 
period of time until most of HPMC was dissolved. 
The result bioadhesive properties of tablet were shown in 
Table No.3. As the concentration of polymer in the 
formulation increase the bioadhesive strength was increase. 
The strength of tablet was dependent on the property of 
mucoadhesive polymers, which adheres to the mucosal 
surface and also on the concentration of polymer used. The 
polymers in the maximum concentration were necessary to 
achieve maximum duration of bioadhesion. The decrease in 
the polymer concentration resulted in decrease in 
bioadhesive time. The primary and secondary polymer in the 
ratio of 1:2, 1:1, 2:1 were used for preparing tablets. The 
highest bond strength was possessed by the formulation 
which containing the more concentration of Carbopol 934P. 
Decreasing the content of the Carbopol 934P resulted in 
decreased adhesion force. But the optimum concentration of 
carbopol 934P is necessary for the bonding with the mucosa. 
The duration of bioadhesion decreased with decreasing 
concentration of Sodium CMC and HPMC. The duration of 
bioadhesion of the formulated bioadhesion tablets were 
determined and found to be around 8 hours except the 
formulation containing sodium CMC.  
Table 3: Bioadhesive properties for Buccoadhesive tablet of 
Lovastatin. 
Formulation 
Code 
Bioadhesive strength 
(gm) 
Bioadhesion time 
(hrs) 
F1 14± 0.117 6.2 
F2 16±0.814 7.0 
F3 18±0.798 7.4 
F4 18±0.547 7.1 
F5 21±0.334 8.0 
F6 22±0.062 8.6 
F7 17±0.144 7.3 
F8 21±0.010 8.2 
F9 23±0.062 8.7 
 
The drug release pattern was studied for all formulations for 
8 hrs and the results are shown in Fig. 4-6. The drug release 
pattern of buccoadhesive tablets varied according to their 
type and ratio of polymers. The most important factor 
affecting the rate of release from buccal tablet is the drug 
and polymer ratio. The formulation F1, F2, F3 contained the 
Carbopol 934p and sodium CMC polymers in the ratio of 1 : 
2, 1: 1 and 2 : 1 respectively. The in vitro drug release profile 
of formulations F1, F2, F3 at 8 hrs showed 83.21%, 86.09% 
and 90.39% drug release respectively. Similarly the 
formulations F4, F5, and F6 contained drug Carbopol 934p 
and HPMC K4M polymers in the ratio of 1 : 2, 1: 1 and 2 : 1 
respectively. The in vitro drug release profile of formulations 
F4, F5 and F6 at 8hrs showed 81.15%, 95.80% and 98.37 
drug release respectively. The formulation F7, F8, F9 
contained the Carbopol 934p and HPMC K100M polymers in 
the ratio of 1: 2, 1: 1 and 2: 1 respectively. The in vitro drug 
release profile of formulations F7, F8, F9 at 8 hrs showed 
77.25%, 92.36% and 96.12% drug release respectively. 
It was concluded that by increasing the concentration of 
Carbopol 934p in the formulations the drug release rate 
from the tablet was found to be decreased, but when the 
concentration of secondary polymers is increase, the drug 
release rate was found to be increased. This may be 
attributed to increased hydration followed by increased 
swelling of polymers with increase in concentration. 
The in-vitro release kinetic studies i.e. zero-order, first order 
and Higuchi and Hixson-Crowell were conducted for all 
formulations and the data is shown in Table-4. The value of 
regression correlation co-efficient (R2) was evaluated for all 
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the formulations which value was close to 0.99. Hence it is 
conducted that all the formulations are following the zero-
order drug release. 
 
Figure 2: Percent Swelling Index of various formulations. 
 
Figure 3: Bioadhesive strength of Lovastatin Tablet 
 
Figure 3: Bioadhesion Time of Lovastatin Tablet 
 
Figure 4: Percent Drug release of Formulation F1, F2, F3 
 
Figure 5: Percent Drug release of Formulation F4, F5, F6. 
 
Figure 6: Percent Drug release of Formulation F7, F8, F9. 
CONCLUSION 
The overall studies indicated that the polymers Carbopol 
934p and HPMC K4M in the ratio of 1:1 showed satisfactory 
mucoadhesive properties. Among the all formulations, the 
formulation F5 using these polymers in the above ratio with 
drug exhibited significant swelling properties with optimum 
release profile. Hence it can be concluded that the 
formulation F5 will be useful for buccal administration for 
the treatment of hypercholesterolemia. So, the 
buccoadhesive tablets of Lovastatin may be a good choice to 
bypass the extensive hepatic first pass metabolism with an 
improvement in the bioavailability of lovastatin through 
Buccal mucosa. 
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